Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

Brooks D J; Sagar H
August 2003
Journal of Neurology, Neurosurgery & Psychiatry;Aug2003, Vol. 74 Issue 8, p1071
Academic Journal
OBJECTIVE: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson's disease with both fluctuating and non-fluctuating response to treatment. METHODS: A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating patients. The clinical efficacy and safety of 200 mg entacapone given with each daily levodopa dose was studied. Efficacy was examined using home diaries, the unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose. RESULTS: The primary efficacy variable for fluctuating patients-the proportion of daily ON time-showed a significant increase compared with placebo (p < 0.05). The absolute ON time (mean (SD)) increased from 9.5 (2.5) to 10.8 (2.4) hours (p < 0.01), and the daily OFF time was correspondingly reduced from 7.0 (2.6) to 5.9 (2.5) hours (p < 0.05 v placebo). This improvement was achieved despite a reduction in daily levodopa requirements. The effect was rapidly lost on withdrawal of entacapone. In non-fluctuating patients, the primary efficacy measure was part II of the UPDRS (activities of daily living; ADL). In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients. CONCLUSIONS: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson's disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.


Related Articles

  • Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol- O-methyltransferase inhibition. Muhlack, Siegfried; Herrmann, Lennard; Salmen, Stephan; Müller, Thomas // Journal of Neural Transmission;Nov2014, Vol. 121 Issue 11, p1357 

    Catechol- O-methyltransferase inhibitor addition to levodopa/carbidopa formulations improves motor symptoms and reduces levodopa fluctuations in patients with Parkinson's disease. Objectives were to investigate the effects of entacapone and tolcapone on plasma behaviour of levodopa, its...

  • Cost Effectiveness of Treatment of Parkinson's Disease with Entacapone in the United States. Palmer, C.S.; Nuijten, M.J.C.; Schmier, J.K.; Subedi, P.; Snyder, E.H. // PharmacoEconomics;2002, Vol. 20 Issue 9, p617 

    Objective: To determine the cost effectiveness of adjunctive therapy with entacapone versus standard treatment (levodopa) without entacapone for patients in the US with Parkinson's disease (PD) who experience ‘off-time’ (re-emergence of the symptoms of PD) while receiving levodopa....

  • Promising research brings hope to Parkinson's patients. Portyansky, Elena // Drug Topics;10/18/99, Vol. 143 Issue 20, p40 

    Provides information on entacapone, an investigational catechol-O-methyltransferase inhibitor for the treatment of Parkinson's disease (PD). Developer of entacapone; Pharmacokinetic influences on lepova; Another treatment for PD patients.

  • Rasagiline, entacapone dominate levodopa in Finland.  // PharmacoEconomics & Outcomes News;12/17/2005, Issue 493, p14 

    This article discusses the results of a study which revealed that rasagiline and entacapone are cost-effective alternatives to levodopa in patients with Parkinson's disease (PD). A Markov model was developed by researchers to assess the 2-year cost effectiveness of several regimens administered...

  • Anti-Parkinson's agent reduces fluctuations, increases `on' time.  // Geriatrics;Nov96, Vol. 51 Issue 11, p19 

    Focuses on the anti-Parkinson's drug entacapone, an agent under the class called catechol-O-methyltransferase (COMT). Drug's effectiveness; Reduction of motor fluctuations; Background on studies conducted on the drug.

  • Comparative Tolerability of the Newer Generation Antiparkinsonian Agents. Lambert, D.; Waters, C.H. // Drugs & Aging;2000, Vol. 16 Issue 1, p55 

    In recent years, the treatment of Parkinson's disease has undergone an immense amount of research, resulting in the development of multiple new medications. This has largely been fuelled by dissatisfaction over the development of motor complications secondary to long term levodopa therapy....

  • Capture Compound Mass Spectrometry Sheds Light on the Molecular Mechanisms of Liver Toxicity of Two Parkinson Drugs. Fischer, Jenny J.; Michaelis, Simon; Schrey, Anna K.; Baessler, Olivia Graebner nee; Glinski, Mirko; Dreger, Mathias; Kroll, Friedrich; Koester, Hubert // Toxicological Sciences;Jan2010, Vol. 113 Issue 1, p243 

    Capture compound mass spectrometry (CCMS) is a novel technology that helps understand the molecular mechanism of the mode of action of small molecules. The Capture Compounds are trifunctional probes: A selectivity function (the drug) interacts with the proteins in a biological sample, a...

  • The use of entacapone in patients with advanced Parkinson's disease: 2 years' experience. Paci, C.; Sanguigni, S.; Carboni, T.; Gobbato, R.; Curatola, L. // Neurological Sciences;Oct2003, Vol. 24 Issue 3, p197 

    Since January 2000 we have administered entacapone (200 mg) to 75 patients with severe Parkinson's disease in combination with their routine levodopa dose. At baseline the mean UPDRS (item III) score was 38±6. After 3 months of entacapone therapy the patients presented a significant...

  • Tolcapone is worth a try when other treatments in patients with fluctuating Parkinson's disease fail or are inappropriate. Adis International Limited // Drugs & Therapy Perspectives;Nov2005, Vol. 21 Issue 11, p1 

    Looks at the role of tolcapone in the treatment of patients with fluctuating Parkinson's disease. Discussion of the efficacy of levodopa with regards to the treatment; Effect of tolcapone on levodopa-induced fluctuations; Comparison of the efficacy of tolcapone with that of entacapone.


Read the Article


Sign out of this library

Other Topics